Adial Pharmaceuticals, Inc
October 28, 2019
Adial Pharmaceuticals Inc (NASDAQ:ADIL) CEO William Stilley tells Proactive the Charlottesville-based biopharma is beginning Phase 3 clinical trials to treat alcoholism in the fourth quarter of this year. Stilley explains that Adial's oral therapy, which aims to reduce the craving for alcohol, can eventually help a patient reduce heavy drinking, or become abstinent.
October 28, 2019
Adial Pharmaceuticals Inc (NASDAQ:ADIL) CEO William Stilley tells Proactive the Charlottesville-based biopharma is beginning Phase 3 clinical trials to treat alcoholism in the fourth quarter of this year. Stilley explains that Adial's oral therapy, which aims to reduce the craving for alcohol, can eventually help a patient reduce heavy drinking, or become abstinent.